secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001818331-23-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q4 revenue $61.4M (+6.2% YoY), full-year net loss $667.6M; 2023 guidance reiterated
--------------------------------------------------------------------------------

- Combined revenue $61.4M in Q4 (+6.2% YoY); full year $234.7M (+10% YoY). Net operating loss $667.6M for FY22.
- Pro forma continuing ops revenue $45.8M in Q4 (+32% YoY); full year $171.0M (+38% YoY). Adjusted gross margin 41% in Q4.
- Completed $150M public offering in Jan 2023; cash position $138.3M at Dec 31, 2022.
- Reiterated FY2023 guidance: revenue $205-220M, cash burn $130-145M, targeting profitability in 2025.
- Whole exome sequencing volume grew 18.8% YoY in Q4; total volume up 25.8%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833123000021/0001818331-23-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833123000021/smfr-20230314.htm
  HTML page:      https://secwatch.observer/filing/0001818331-23-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer